Targeting RNA Congress
Nearly 100% of all small molecule drugs in the market are designed to target proteins. However, only 2% of the human genome actually codes for proteins, leaving the remaining noncoding DNA and in turn RNA as potentially untapped therapeutic targets.
To date, industry has focused on biological products for RNA therapeutics but the emergence of epitranscriptomics and bioinformatics tools has provided the field with a new range of drug modalities. This has led to increasing capital investment alongside collaborations within pharma and biotech to assess if RNA can be a drug target.
The Targeting RNA Congress will explore the ‘undruggable’ RNA space and showcases the latest advancements in modulation of RNA directly with small molecules and through epigenetics. The meeting will bring together academic and industry leaders who are building platforms to identify and validate targets in order to assess disease relevance approaches in the RNA world. You’ll take away actionable insights including:
- Strategies to go from hit-to-lead candidates
- Addressing structural biology, biochemical and biophysical attributes relevant for RNA
- Approaches to overcome chemical hurdles associated with new drug discovery platforms
- How mapping RNA upstream regulation can develop disease prevention products
“This meeting is an excellent opportunity to interact with one of the best collections of thought leaders and drug discovery experts in the field of epitranscriptomics, and I am looking forward to exchanging strategic insights with my colleagues aiming at unlocking an entire class of previously undruggable targets” – Dr. Gerhard Mueller, Chief Scientific Officer, Gotham Therapeutics
To learn more about Targeting RNA Congress and to register online, visit: https://go.kisacoresearch.com/l/678123/2019-09-16/ldwx